Items Tagged ‘NACT’

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed advanced ovarian cancer. While the standard of care in this setting is primary cytoreductive surgery (PCS) followed […]